Share on StockTwits

Solazyme (NASDAQ:SZYM) General Counsel Paul T. Quinlan unloaded 8,500 shares of the stock on the open market in a transaction that occurred on Tuesday, August 19th. The stock was sold at an average price of $9.43, for a total value of $80,155.00. Following the sale, the general counsel now directly owns 86,875 shares of the company’s stock, valued at approximately $819,231. The transaction was disclosed in a filing with the SEC, which is available at this link.

Separately, analysts at Morgan Stanley reiterated an “overweight” rating on shares of Solazyme in a research note on Friday, May 30th. They now have a $15.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and one has given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $15.00.

Solazyme (NASDAQ:SZYM) traded down 1.25% during mid-day trading on Wednesday, hitting $9.49. 34,873 shares of the company’s stock traded hands. Solazyme has a 52-week low of $8.00 and a 52-week high of $15.00. The stock’s 50-day moving average is $9.96 and its 200-day moving average is $11.01. The company’s market cap is $746.8 million.

Solazyme (NASDAQ:SZYM) last issued its quarterly earnings data on Wednesday, July 30th. The company reported ($0.43) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.36) by $0.07. The company had revenue of $15.94 million for the quarter, compared to the consensus estimate of $17.13 million. During the same quarter last year, the company posted ($0.28) earnings per share. Solazyme’s revenue was up 42.6% compared to the same quarter last year. Analysts expect that Solazyme will post $-1.71 EPS for the current fiscal year.

Solazyme, Inc operates as a renewable oil production company. The Company fuels include microbial-derived jet fuels, bio-diesels, and renewable diesels.

Receive News & Ratings for Solazyme Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solazyme Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.